IDRA-21

Chemical identity

IDRA-21 is a benzothiadiazine dioxide — structurally a relative of the thiazide diuretics and of diazoxide, from which the ampakine class was originally derived. It is not a racetam, and grouping it with them reflects shared research application rather than shared chemistry.

The 3-methyl substituent creates a chiral centre. The enantiomers differ in potency, and commercial material is typically racemic unless the certificate states otherwise.

Mechanism in research models

IDRA-21 is a positive allosteric modulator of AMPA receptors acting, like aniracetam, by attenuating receptor desensitisation. Its reported potency in this action is roughly an order of magnitude greater than aniracetam's, which is why it became a standard tool compound in the field.

The binding site is at the dimer interface of the receptor's ligand-binding domain — the same region targeted by cyclothiazide and the CX-series ampakines. This site is structurally well characterised, which distinguishes IDRA-21's mechanism from the vagueness surrounding most racetams.

By enhancing AMPA-mediated depolarisation, the compound facilitates NMDA receptor activation indirectly through relief of magnesium block, providing a plausible route to the effects on long-term potentiation reported in slice work.

What the literature establishes

The electrophysiological characterisation is genuinely strong. Effects on AMPA receptor desensitisation kinetics are direct, measurable and reproducible, and the compound is used as a positive control in ampakine pharmacology.

Behavioural work includes studies in non-human primates reporting improved performance on delayed matching-to-sample tasks, which is a more demanding paradigm than the rodent maze work supporting most compounds in this category.

There is no human clinical data. The wider ampakine class has a known dose-dependent liability for excitotoxicity — excessive AMPA-mediated calcium entry — which is the central safety consideration for any work with these compounds and should shape concentration ranges from the outset.

Handling, storage and solubility

Typically held sealed at −20 °C, protected from light and moisture, and stable as a dry solid; the validated condition is the one stated on the lot documentation.

Poorly water-soluble; soluble in DMSO and, to a lesser extent, ethanol. Prepare DMSO stocks, dilute into buffer immediately before use, and confirm no precipitation at the working concentration — benzothiadiazides commonly crash out of aqueous buffer at concentrations the calculation says are fine.

Include vehicle-matched controls. DMSO has its own effects on neuronal preparations and on receptor kinetics at concentrations well below those that affect viability.

Analytical documentation

Require HPLC purity, NMR and mass confirmation. The chlorinated aromatic ring gives a characteristic isotope pattern in mass spectrometry — a 3:1 M/M+2 ratio — which is a quick and reliable confirmation that chlorine is present as expected.

Where enantiomeric composition is relevant, request chiral analysis explicitly; it is not part of a standard certificate.

References and authoritative sources

Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.

1. PubChem compound record (US National Library of Medicine)
2. PubMed indexed literature

These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.